Clinical Ophthalmology.
People Policies Reception of articles Other

Efficacy and tolerability of a specialized dietary therapeutic product in long-chain and very long-chain fatty acid metabolism disorders 
in children

Abstract

DOI: 10.32364/2618-8430-2021-4-1-98-102

Aim: to assess the efficacy and tolerability of a specialized dietary therapeutic product in long-chain and very long-chain fatty acid metabolism disorders in children.

Patients and Methods: this open-label prospective uncontrolled study enrolled 5 children aged 35 ± 14 months who were diagnosed with long-chain and very long-chain fatty acid metab-olism disorders. Diet therapy using the tested product (“Monogen”) was prescribed and corrected after the analysis of actual diet. Physical development and neurological status were evaluated, blood levels of specific acyl-carnitines (С16-ОН,
С18-ОН, С18:1-ОН, С14:1, С14) were measured. Tolerability was assessed by the rate and severity of adverse events (including allergic reactions) and the changes in vital functions compared to baseline. Patient and doctor satisfaction was evaluated using a questionnaire.

Results: children received the tested product throughout the study (30±2 days). The lev-els of acyl-carnitines were within normal ranges in all children. No dyspepsia, allergic reactions, somatic dysfunction, or neurological deviations were reported. Physical exam consistently fell in the range of normal for age. Parents and doctors were fully satisfied with the tested product (“Monogen”).

Conclusions: “Monogen” is highly effective for therapeutic feeding of children with long-chain and very long-chain fatty acid metabolism disorders.

Keywords: long-chain fatty acid oxidation disorders, β-oxidation of fatty acids, long-chain acyl-coA dehydrogenase deficiency, biallelic mutation, therapeutic feeding.

About the authors:

Nataliya A. Semenova — Cand. of Sci. (Med.), geneticist of the highest category, senior researcher of the Research Center for Medical Genetics; 1, Moskvorechye str., Moscow, 115522, Russian Federation; ORCID iD 0000-0001-7041-045X.

Elena A. Shestopalova — geneticist of the highest category, Research Center for Medical Genetics; 1, Moskvorechye str., Moscow, 115522, Russian Federation; ORCID iD 0000-0003-2151-6025.

Sergey I. Kutsev — Doct. of Sci. (Med.), Professor, Corresponding Member of RAS, Director of the Research Center for Medical Genetics; 1, Moskvorechye str., Moscow, 115522, Russian Federation; ORCID iD 0000-0002-3133-8018.

Contact information: Nataliya A. Semenova, e-mail: Semenova@med-gen.ru. Financial Disclosure: no authors have a financial or property interest in any material or method mentioned. The study was supported by “Nutricia”. Received 10.11.2020, revised 03.12.2020, accepted 28.12.2020.

References
1. Mikhailova S.V., Zakharova E.Yu., Petrukhin A.S. Neurometabolic diseases in children and adolescents: diagnosis and treatment approaches. 2nd ed. M.: Litterra; 2019 (in Russ.). 2. Iacobazzi V., Pasquali M., Singh R. et al. Response to therapy in carnitine/acylcarnitine translocase (CACT) deficiency due to a novel missense mutation. Am J Med Genet. 2004;126A (2):150–155. DOI: 10.1002/ajmg.a.20573. 3. Fernandes J., Saudubray J-M., van den Berghe G., Walter J.H. (Eds.). Inborn Metabolic Diseases. Fourth, Revised Edition. Springer Medizin Verlag Heidelberg; 2006. 4. Deficiency of acyl-CoA dehydrogenase of fatty acids with a very long carbon chain in children. Clinical guidelines. M.; 2016 (in Russ.). 5. Zhurba L.T., Mastyukova E.M. Violation of the psychomotor development of children in the first year of life. M.: Medicine; 1981. 6. Spiekerkoetter U., Bastin J., Gillingham M. et al. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J Inherit Metab Dis. 2010;33:555–561. DOI: 10.1007/s10545-010-9188-1. 7. Rohr F., van Calcar S. Genetic metabolic international guidelines for VLCADD, 2008. (Electronic resource.) URL: www.gmdi.org. (access date: 10.12.2020).

License Creative Commons
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Read the article in PDF in Russian


Previous article
Next article
0
9525
Analysis of central retinal microcircula...
0
2178
All articles

Распечатать